<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-Q

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

     For the quarterly period ended September 29, 2001

                                      OR

[_]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the transition period from ___________ to ___________________.


                         COMMISSION FILE NUMBER 0-21667

                           PHOTOELECTRON CORPORATION
             (Exact Name of Registrant as Specified in its Charter)


             MASSACHUSETTS                                       04-3035323
   (State or Other Jurisdiction of                            (I.R.S. Employer
   Incorporation or Organization)                            Identification No.)

             5 FORBES ROAD,                                          02421
       LEXINGTON, MASSACHUSETTS                                    (Zip code)
(Address of Principal Executive Offices)

                                 (781) 861-2069
              (Registrant's Telephone Number, Including Area Code)

                                  -----------

     Indicate by check mark whether the registrant: (1) has filed all documents
and reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports) and (2) has been subject
to such filing requirements for the past 90 days. Yes [X] No [_]

                                  -----------

     9,947,418 shares of Common Stock, $.01 par value, were outstanding as of
November 9, 2001.
<PAGE>

                           PHOTOELECTRON CORPORATION

                         QUARTERLY REPORT ON FORM 10-Q
                    FOR THE PERIOD ENDED SEPTEMBER 29, 2001

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                              Page
                                                                                                              ----
PART I--   FINANCIAL INFORMATION

<S>                                                                                                         <C>
Item 1     Consolidated Financial Statements.............................................................      3

           Consolidated Balance Sheets at September 29, 2001 and December 30, 2000.......................      3

           Consolidated Statements of Operations for the Three and Nine Months Ended September 29, 2001        4
           and September 30, 2000........................................................................

           Consolidated Statements of Cash Flows for the Nine Months Ended September 29, 2001                  5
           and September 30, 2000........................................................................

           Notes to Unaudited Consolidated Financial Statements..........................................      6

Item 2     Management's Discussion and Analysis of Financial Condition and Results of Operations.........      7

PART II--  OTHER INFORMATION

Item 1     Legal Proceedings.............................................................................     10

Item 2     Changes in Securities and Use of Proceeds.....................................................     10

Item 3     Defaults upon Senior Securities...............................................................     10

Item 4     Submission of Matters to a Vote of Security Holders...........................................     10

Item 5     Other Information.............................................................................     10

Item 6     Exhibits and Reports on Form 8-K..............................................................     10
</TABLE>

                                       2

<PAGE>

                    PHOTOELECTRON CORPORATION AND SUBSIDIARY

                          CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                     September 29,         December 30,
                                                                                     -------------         ------------
                                                                                          2001                 2000
                                                                                          ----                 ----
                                                                                       (Unaudited)
<S>                                                                                <C>               <C>
                                    ASSETS
Current Assets:
  Cash and cash equivalents......................................................     $  2,735,762        $    662,857
  Accounts receivable............................................................          172,746             278,743
  Inventories....................................................................        1,635,755           1,389,710
  Prepaid expenses...............................................................          231,466             295,588
  Held to maturity investments...................................................               --           3,972,770
                                                                                      ------------        ------------
     Total current assets........................................................        4,775,729           6,599,668
                                                                                      ------------        ------------
Property and Equipment:
  Computer equipment.............................................................        1,026,534             984,237
  Lab and production equipment...................................................        1,168,960           1,068,793
  Clinical site equipment........................................................          875,122             875,122
  Sales demo equipment...........................................................          148,450             148,450
  Furniture and fixtures.........................................................          183,104             183,104
  Leasehold improvements.........................................................          866,230             866,230
                                                                                      ------------        ------------
  Property and equipment.........................................................        4,268,400           4,125,936
  Less--Accumulated depreciation and amortization................................        3,751,336           3,384,127
                                                                                      ------------        ------------
  Net property and equipment.....................................................          517,064             741,809
                                                                                      ------------        ------------
Other Assets:
  Deferred offering costs, net...................................................          920,712           1,106,422
                                                                                      ------------        ------------
     Total assets................................................................     $  6,213,505        $  8,447,899
                                                                                      ============        ============

                    LIABILITIES AND SHAREHOLDERS' (DEFICIT)
Current Liabilities:
  Accounts payable...............................................................     $    566,444        $    218,614
  Accrued expenses...............................................................          524,177             569,447
  Accrued payroll and benefits...................................................           85,457             223,901
                                                                                      ------------        ------------
     Total current liabilities...................................................        1,176,078           1,011,962
                                                                                      ------------        ------------
Long Term Liabilities
  10% senior convertible debentures..............................................        9,904,221          10,727,361
                                                                                      ------------        ------------
Shareholders' (Deficit):
  Preferred stock, $0.01 par value
     Authorized--2,500,000
     Issued and outstanding--none at September 29, 2001 and December 30,
      2000, respectively.........................................................               --                  --

  Common stock, $0.01 par value
     Authorized--20,000,000
     Issued and outstanding--9,914,008 and 8,551,685 at September 29, 2001
      and December 30, 2000, respectively........................................           99,140              85,517

  Capital in excess of par value common stock....................................       48,253,046          42,943,997
  Deferred compensation..........................................................          (88,256)            (82,047)
  Accumulated deficit............................................................      (53,130,724)        (46,238,891)
                                                                                      ------------        ------------
     Total shareholders' (deficit)...............................................       (4,866,794)         (3,291,424)
                                                                                      ------------        ------------
     Total liabilities and shareholders' (deficit)...............................     $  6,213,505        $  8,447,899
                                                                                      ============        ============
</TABLE>


   The accompanying notes are an integral part of these financial statements.

                                       3
<PAGE>

                    PHOTOELECTRON CORPORATION AND SUBSIDIARY

                     CONSOLIDATED STATEMENTS OF OPERATIONS

<TABLE>
<CAPTION>
                                                  Three Months Ended                Nine Months Ended
                                             -----------------------------  ---------------------------------
                                             September 29,    September 30    September 29,     September 30,
                                                 2001             2000            2001             2000
                                             -------------  --------------  ----------------  ---------------
                                              (Unaudited)    (Unaudited)      (Unaudited)       (Unaudited)
<S>                                          <C>            <C>             <C>               <C>
Revenues...................................   $   157,585     $   167,960       $   760,365      $ 1,120,509
Cost of Goods Sold.........................        90,825          62,150           479,728          401,967
                                              -----------     -----------       -----------      -----------
Gross Margin...............................        66,760         105,810           280,637          718,542
                                              -----------     -----------       -----------      -----------
Operating Expenses
  Research and development
    Expenses...............................   $ 1,236,850     $   811,460       $ 3,040,524      $ 2,284,286
  Sales, general and administrative
    Expenses...............................     1,132,777         899,184         3,562,633        2,608,587
                                              -----------     -----------       -----------      -----------
    Total operating expenses...............     2,369,627       1,710,644         6,603,157        4,892,873
                                              -----------     -----------       -----------      -----------
    Operating loss.........................    (2,302,867)     (1,604,834)       (6,322,520)      (4,174,331)
Interest income............................        31,284          93,114           191,963          131,042
Interest expense...........................      (241,082)       (331,594)         (761,274)      (1,572,592)
                                              -----------     -----------       -----------      -----------
Interest expense, net......................      (209,798)       (238,480)         (569,311)      (1,441,550)
                                              -----------     -----------       -----------      -----------
Net loss...................................   $(2,512,665)    $(1,843,314)      $(6,891,831)     $(5,615,881)
                                              ===========     ===========       ===========      ===========
Basic and diluted net loss per share.......
                                              $     (0.25)    $     (0.23)      $     (0.72)     $     (0.72)
                                              ===========     ===========       ===========      ===========
Weighted average basic and diluted shares..     9,912,370       7,873,775         9,627,677        7,834,904
                                              ===========     ===========       ===========      ===========
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                       4
<PAGE>

                   PHOTOELECTRON CORPORATION AND SUBSIDIARY

                     CONSOLIDATED STATEMENTS OF CASH FLOW

<TABLE>
<CAPTION>
                                                                                                  Nine Months Ended
                                                                                       ----------------------------------------
                                                                                       September 29, 2001   September 30, 2000
                                                                                       -------------------  -------------------
                                                                                           (Unaudited)          (Unaudited)
<S>                                                                                    <C>                  <C>
Cash flows from operating activities:
 Net loss............................................................................         $(6,891,831)         $(5,615,881)
 Adjustments to reconcile net loss to net cash used in operating activities--
  Depreciation and amortization......................................................             367,208              387,017
  Amortization of offering expenses..................................................             160,879               64,503
  Noncash compensation expense.......................................................              44,041               23,556
  Noncash interest converted to  notes...............................................                  --               82,828
  Noncash commission expense.........................................................                  --                7,481
  Noncash consulting expense.........................................................               9,106              186,842
  Noncash interest expense on bridge financing.......................................                  --              638,696
  Noncash interest expense on 10% senior convertible debentures......................             761,274              851,068
 Changes in current accounts--
  Inventories........................................................................            (246,045)             161,568
  Accounts receivable................................................................             105,997             (178,321)
  Prepaid expenses...................................................................              64,122             (201,608)
  Other current assets...............................................................                  --               26,184
  Accounts payable...................................................................             347,830              (58,513)
  Accrued expenses...................................................................            (183,714)            (128,537)
  Deferred revenue...................................................................                  --              (87,500)
                                                                                              -----------          -----------
   Net cash used in operating activities.............................................          (5,461,133)          (3,840,617)
                                                                                              -----------          -----------
Cash flows from investing activities:
 Proceeds from (Purchase of) held to maturity investments............................           3,972,770           (4,019,249)
 Purchases of equipment and leasehold improvements...................................            (142,464)            (218,176)
                                                                                              -----------          -----------
  Net cash provided by (used in) investing activities................................           3,830,306           (4,237,425)
                                                                                              -----------          -----------
Cash flows from financing activities:
 Proceeds from issuance of common stock..............................................           3,881,109            1,863,251
 Proceeds from issuance of convertible notes payable.................................                  --            1,450,000
 Proceeds from issuance of 10% senior convertible debentures.........................                  --            7,360,000
 Deferred offering expenses..........................................................            (177,377)            (707,378)
                                                                                              -----------          -----------
  Net cash provided by financing activities..........................................           3,703,732            9,965,873
                                                                                              -----------          -----------
Increase in cash and cash equivalents................................................           2,072,905            1,887,831
                                                                                              -----------          -----------
Cash and cash equivalents, beginning of period.......................................             662,857              134,104
                                                                                              -----------          -----------
Cash and cash equivalents, end of period.............................................         $ 2,735,762          $ 2,201,935
                                                                                              -----------          ===========
Noncash financing activities:
 Non cash deferred offering expenses.................................................                  --          $   591,787
                                                                                              ===========          ===========
 Conversion of 10% Senior Convertible Debentures to common stock.....................         $ 1,568,241          $ 3,098,909
                                                                                              ===========          ===========
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                       5
<PAGE>

                           PHOTOELECTRON CORPORATION

              NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1.   Unaudited Results

  The interim unaudited consolidated financial statements contained herein have
been prepared in accordance with generally accepted accounting principles for
interim financial information.  Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements.  In management's opinion, the unaudited
information includes all adjustments (consisting of normal recurring entries)
necessary for a fair presentation of the financial position, results of
operations, and cash flows for the periods presented.  The results of operations
for the interim periods shown on this report are not necessarily indicative of
the results expected for the full year.  The interim financial statements should
be read in conjunction with the financial statements and notes for the year
ended December 30, 2000 included in the Company's Annual Report on Form 10-K
filed with the Securities and Exchange Commission.

2.   Net Loss Per Share

  During the first nine months of 2001 and 2000, basic and diluted net loss per
share were calculated as follows:

<TABLE>
<CAPTION>
                                               Three Months Ended                Nine Months Ended
                                        --------------------------------  --------------------------------
                                         September 29,    September 30,    September 29,    September 30,
                                             2001             2000             2001             2000
                                        ---------------  ---------------  ---------------  ---------------
<S>                                     <C>              <C>              <C>              <C>
  Basic:
     Net loss.........................     $(2,512,665)     $(1,843,314)     $(6,891,831)     $(5,615,881)
     Weighted average shares..........       9,912,370        7,873,775        9,627,677        7,834,904
     Basic net loss per share.........     $     (0.25)     $     (0.23)     $     (0.72)     $     (0.72)
</TABLE>

  The computation of diluted earnings per share for September 29, 2001 and
September 30, 2000 excludes the effect of assuming the exercise of certain
outstanding stock options and the conversion of convertible securities because
the effect would be anti-dilutive, due to the Company's net loss during the
period.  As of September 29, 2001, there were 980,707 of such options
outstanding, with exercise prices ranging from $2.125-$9.00 per share with
expiration dates ranging from October 25, 2001 to July 31, 2011.  As of
September 29, 2001, there were securities convertible into 3,459,055 shares of
common stock, with conversion prices ranging from $2.45-$4.74 per share with
expiration dates ranging from January 27, 2002 to June 30, 2005.

3.   Comprehensive Income (loss)

   The Company applies the provisions of Statement of Financial Accounting
Standards (SFAS) No. 130, "Reporting Comprehensive Income." This pronouncement
sets forth requirements for disclosure of the Company's comprehensive income
(loss) and accumulated other comprehensive income (loss). There were no items of
other comprehensive income (loss); therefore comprehensive income (loss) equals
net loss.

4.  Senior Convertible Debt

  In June 2000, the Company issued in a private placement $10,458,909 of 10%
senior convertible debentures.  The Company is using the net proceeds of the
private placement for general and administrative expenses, refinancing of short-
term debt bridge financing and general corporate purposes, including, without
limitation, to support the accelerated testing and marketing of the Company's
new products.

  The holders of the debentures are entitled to receive interest payments at the
rate of 10% per annum on the outstanding principal amount of the debentures.  At
the option of the Company, interest may be paid when due by adding the amount
payable to the outstanding principal amount of the debentures.  The Company
exercised that option, and added an aggregate of $241,081 and $745,098 to the
outstanding principal amount of the 10% senior convertible debentures for the
three and nine months ended September 29, 2001, respectively.

  The principal amount of the debentures, together with all accrued and unpaid
interest, is due and payable on May 1, 2005.  The holders of the debentures have
the option, at any time prior to May 1, 2005, to convert the debentures, in
whole or in part, into shares of the Company's common stock at a price of $4.00
per share.

                                       6
<PAGE>

                        PART I:   FINANCIAL INFORMATION

Item 2: Management's Discussion and Analysis of Financial Condition and
        Results of Operations.

 Overview

     Certain statements contained in this Quarterly Report on Form 10-Q,
including, without limitation, statements containing the words "expects,"
"anticipates," "believes" and words of similar import, constitute "forward
looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward looking statements are subject to various
risks and uncertainties, including those referred to in the Company's Annual
Report on Form 10-K for the fiscal year ended December 30, 2000, that could
cause actual future results and events to differ materially from those currently
anticipated. Readers are cautioned not to place undue reliance on these forward-
looking statements.

     Photoelectron Corporation (the "Company" or "PeC') is a technology company
dedicated to developing, manufacturing and marketing miniature x-ray systems for
multiple market applications.

     Established in 1989, the Company initially focused on research and
development for the miniaturization of an x-ray system for cancer treatment.
PeC has since expanded its development efforts and is now creating and adapting
miniature x-ray systems for a variety of applications in healthcare and non-
healthcare related markets. The various miniature x-ray products based on the
Company's extensive research and development program are known collectively as
"micro-adaptive x-ray systems."  The Company has established an intellectual
property portfolio of twenty-one (21)  U.S. patents and has nine (9) additional
U.S. patents pending, all of which relate to the Company's core technology and
use.

     The Company's business strategy is to identify opportunities in which its
patented core technology can be used to gain access to new markets by means of
strategic alliances with industry leaders. This strategy allows PeC to foster
the development of multiple applications of its technology, while remaining
focused on its core expertise of developing, manufacturing and marketing micro-
adaptive x-ray systems.  By joining with one or more industry leaders to develop
an x-ray system to satisfy the needs of a specific market, the Company gains
market and application expertise without having to internalize many of the costs
and organizational overhead necessary to support the specific application.
Leveraging the market expertise of these strategic relationships allows the
Company to rapidly bring the technology to new markets.  The Company plans to
identify additional market opportunities that can both be linked to the core
technology and present the opportunity to access the market through a strategic
partner with application expertise and the sales and marketing organization
necessary to drive market acceptance.

     The Company is currently pursuing initiatives in the industrial and medical
markets with micro-adaptive x-ray systems designed for x-ray fluorescence
analysis, intravascular radiation therapy, brachytherapy, radiosurgery, intra-
operative radiation therapy, and instrumentation.

     The Company has experienced significant operating losses in each year since
its inception, due primarily to substantial research and development
expenditures.  As of September 29, 2001, the Company had an accumulated deficit
of approximately $53 million and expects to continue to incur losses until such
time as its commercialization efforts yield offsetting revenues.  There can be
no assurance that the Company's products will ever gain commercial acceptance,
or that the Company will ever generate significant revenues or achieve
profitability.  The Company's ability to achieve profitable operations will be
dependent in a large part on whether it can successfully commercialize its
products and make the transition to a manufacturing and marketing company.  The
Company anticipates that its sales and marketing efforts through its existing
sales and distribution channels will continue to increase sales of its products
in the current year.  The Company anticipates that its research and development,
sales and general and administrative expenses will increase during 2001 to
support continued development and distribution.

 Results of Operations

 Three Months Ended September 29, 2001 and September 30, 2000

     Revenue. The Company had revenue of $157,585 in the third quarter of 2001,
as compared with $167,960 in the third quarter of 2000. The third quarter 2001
revenue reflects the sale of a core Photon Radiosurgery System (the "PRS") to
the University of Heidleberg, Germany, combined with continued sales of the
LASER-X(TM) industrial x-ray source ("LASER-X"). The 2000 revenue can be
attributed to a partial shipment of an INTRABEAM(TM) system ("INTRABEAM") in
addition to the shipment of a microdensitometer.

                                       7
<PAGE>

     Research and development expenses.  The Company's research and development
expenses increased by $425,390 from $811,460 in the third quarter of 2000 to
$1,236,850 in the third quarter of 2001.  The increase primarily represents the
continued development of the new miniature x-ray sources for intravascular
radiation therapy (X-SEED(TM)) and x-ray fluorescence systems (LASER-X).

     Selling, general and administrative expenses. The Company's selling,
general and administrative expenses increased by $233,593 from $899,184 in the
third quarter of 2000 to $1,132,777 in the third quarter of 2001. The increase
is primarily attributable to expenses incurred as a result of the continuing
sales and marketing initiative which commenced in 2000. The initiative is aimed
at raising awareness of PeC products and technologies in the medical, non-
medical, patient and investment communities.

     Interest income.   Interest income decreased by $61,962 from $93,114 in the
third quarter of 2000 to $31,284 in the third quarter of 2001. The decrease
resulted from a decrease in amounts invested as well as a decrease in prevailing
market interest rates.

     Interest expense. Interest expense decreased by $90,644 from $331,594 in
the third quarter of 2000 to $241,082 in the third quarter of 2001. The majority
of this decrease resulted from reduced interest expense related to the Company's
$10.4 million 10% senior convertible debenture private placement which closed in
June 2000.

 Nine Months Ended September 29, 2001 and September 30, 2000

     Revenue.   The Company had revenues of $760,365 in the first nine months of
2001, as compared with $1,120,509 in the first nine months of 2000.  The 2001
revenue reflects shipments of the LASER-X combined with the shipment of
INTRABEAMs and Dosimetry product sales.  The 2000 revenue is primarily the
result of the Company shipping INTRABEAMs and a microdensitometer.

     Research and development expenses.  The Company's research and development
expenses increased by $756,238 from $2,284,286 in the first nine months of 2000
to $3,040,524 in the first nine months of 2001.  The increase primarily
represents the continued development of the new miniature x-ray sources for
intravascular radiation therapy and x-ray fluorescence systems.

     Selling, general and administrative expenses. The Company's selling,
general and administrative expenses increased by $954,046 from $2,608,587 in the
first nine months of 2000 to $3,562,633 in the first nine months of 2001. The
increase is primarily attributable to expenses incurred as a result of the sales
and marketing initiative which commenced in 2000. The initiative is aimed at
raising awareness of PeC products and technologies in the medical, non-medical,
patient and investment communities.

     Interest income. Interest income increased by $60,789 from $131,042 in the
first nine months of 2000 to $191,963 in the first nine months of 2001. The
increase resulted from an increase in amounts invested attributable to the
Company's $10.4 million 10% senior convertible debenture private placement which
closed in June 2000 and Johnson & Johnson Development Corporation's purchase of
shares of the Company's common stock for an aggregate purchase price of $3.8
million in February 2001.

     Interest expense. Interest expense decreased by $811,450 from $1,572,592 in
the first nine months of 2000 to $761,274 in the first nine months of 2001. The
decrease resulted from reduced interest expense related to the Company's $10.4
million 10% senior convertible debenture private placement which closed in June
2000.

 Backlog

     The Company ended the third quarter of 2001 with open orders of $869,797,
as compared to a backlog of $319,500 for the third quarter of 2000. The 2001
unshipped orders relate primarily to LASER-X industrial x-ray systems which are
being delivered according to an agreed upon delivery schedule. The Company
expects to ship the majority of the existing open orders through March 2002.

                                       8
<PAGE>

Liquidity and Capital Resources

     The Company has expended substantial funds to research and develop the PRS,
INTRABEAM, LASER-X, X-SEED and other potential products, conduct clinical
trials, pursue regulatory approvals, establish commercial scale manufacturing in
its own facilities or in the facilities of others, and market the PRS,
INTRABEAM, LASER-X, X-SEED and other products. The Company anticipates it will
continue to expend substantial funds in the future on such activities as such
funds become available.

     Since its inception, the Company has financed its operations through the
issuance of convertible debt and equity in a series of private placements
totaling approximately $35.4 million and its initial public offering with net
proceeds of $16,818,854.

     Consolidated working capital was $3,599,651 at September 29, 2001, compared
with $5,587,706 at December 30, 2000. Included in working capital are cash and
cash equivalents of $2,735,762 at September 29, 2001, compared with $662,857 at
December 30, 2000, and no investments held to maturity at September 29, 2001,
compared with $3,972,770 at December 30, 2000. During the first nine months of
2001, the Company used $5,461,133 of cash for operating activities as compared
to $3,840,617 for the first nine months of 2000.

     The Company used $142,464 of cash in the first nine months of 2001 for
fixed assets and leasehold improvements associated with its facility.

     The Company received an aggregate of $4,988 and $76,860 of cash from the
exercise of stock options to purchase common stock for the three and nine months
ended September 29, 2001, respectively.

     In June 2000, the Company issued in a private placement $10,458,909 of 10%
senior convertible debentures.  The Company is using the net proceeds of the
private placement for general and administrative expenses, refinancing of
$2,312,755 of short-term debt bridge financing provided by PYC Corporation and
$786,153 due under an 8% Subordinated Convertible Demand Note to Peter M.
Nomikos, and for general corporate purposes, including, without limitation, to
support the accelerated testing and marketing of the Company's new products.

     The holders of the 10% senior convertible debentures are entitled to
receive interest payments at the rate of 10% per annum on the outstanding
principal amount of the debentures. At the option of the Company, interest may
be paid when due by adding the amount payable to the outstanding principal of
the debentures. The principal amount of the debentures, together with all
accrued and unpaid interest, is due and payable on May 1, 2005. The holders of
the debentures have the option, at any time prior to May 1, 2005, to convert the
debentures, in whole or in part, into shares of the Company's common stock at a
price of $4.00 per share.

     On February 5, 2001, Johnson & Johnson Development Corporation purchased
904,762 shares of the Company's common stock for an aggregate purchase price of
$3.8 million.

     The Company maintains medical product liability insurance policies with
respect to its clinical trials which the Company believes contain reasonable
deductibles and other ordinary and customary provisions.  The Company believes
that these policies cover such risks in such amounts as are reasonable and
prudent under the circumstances, and the Company does not anticipate that claims
under these policies, if any, will have a material adverse impact on the
Company's liquidity or capital resources.  Prior to commercial sale of its
products, the Company obtained product liability insurance covering the
commercial use of its products.

     The Company's future capital requirements will depend on a variety of
factors, including the time and costs involved in obtaining United States Food
and Drug Administration and other regulatory approvals, the results of the
Company's ongoing clinical trials, the market acceptance of the PRS, INTRABEAM,
LASER-X, X-SEED and any other Company products, the expense and results of the
Company's continued scientific research and development programs, the time and
costs expended in filing, prosecuting and enforcing patent claims, and the
development of competing technologies.

     The Company believes that its existing cash and investments together with
anticipated revenues will be sufficient until at least the end of fiscal 2001.
The Company is currently evaluating opportunities to raise additional capital in
fiscal 2001.  There is no assurance that it will be able to find additional
financing on acceptable terms, if at all.

                                       9
<PAGE>

                          PART II:   OTHER INFORMATION

Item 1: Legal Proceedings

        Not Applicable

Item 2: Changes in Securities and Use of Proceeds

        Not Applicable

Item 3: Defaults upon Senior Securities

        Not Applicable

Item 4: Submission of Matters to a Vote of Security Holders

        Not Applicable

Item 5: Other Information

        None

Item 6: Exhibits and Reports on Form 8-K.

        (A)   Exhibits

        None

        (B)   Reports on Form 8-K

        No reports on Form 8-K have been filed during the quarter for which this
        report is filed.

                                       10
<PAGE>

                                   SIGNATURES

  Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                  Photoelectron Corporation


                                  By: /s/ Euan S. Thomson
                                      -------------------
                                      Euan S. Thomson
                                      President and Chief Executive Officer


                                  By: /s/ Timothy W. Baker
                                      --------------------
                                      Timothy W. Baker
                                      Chief Financial Officer

Dated:  November 13, 2001

                                       11